ImmunityBio's Commercial Validation: Revenue Soars on Key Drug Launch

ImmunityBio has delivered compelling evidence that its flagship therapy, ANKTIVA, is achieving significant commercial traction. While regulatory approvals in Europe and robust clinical data have ...

Ocugen Reaches Critical Enrollment Target in Key Gene Therapy Trial

Ocugen maintains its guidance to submit a rolling Biologics License Application (BLA) for OCU400 in the third quarter of 2026. A rolling submission allows the company to present completed sections of ...

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and ...

argenex Q4 Earnings Call Highlights

(NASDAQ:ARGX) used its fourth-quarter earnings call to highlight positive Phase 3 data in ocular myasthenia gravis (MG), continued commercial momentum for VYVGART, and its first year of annual ...
The Manila Times

GATC Health Strengthens Commercial and Pharma Strategy Leadership to Accelerate Market Adoption of Its AI Platform

Mark Flather and Dr. Fred Brown join to expand adoption of Derisq™ and Operon™, delivering AI-powered risk prediction and portfolio optimization for biotech investors and pharmaceutical ...